[1]马艳艳,刘建军.肌无力危象的治疗研究进展[J].医学信息,2019,32(06):45-47.[doi:10.3969/j.issn.1006-1959.2019.06.016]
　MA Yan-yan,LIU Jian-jun.Progress in the Treatment of Myasthenia Crisis[J].Journal of Medical Information,2019,32(06):45-47.[doi:10.3969/j.issn.1006-1959.2019.06.016]
点击复制

肌无力危象的治疗研究进展()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年06期
页码:
45-47
栏目:
综述
出版日期:
2019-03-15

文章信息/Info

Title:
Progress in the Treatment of Myasthenia Crisis
文章编号:
1006-1959（2019）06-0045-03
作者:
马艳艳; 刘建军
（西安医学院附属西安高新医院神经内科，陕西 西安 710075）
Author(s):
MA Yan-yan; LIU Jian-jun
(Department of Neurology,Xi'an High-tech Hospital affiliated to Xi'an Medical College,Xi'an 710075,Shaanxi,China)
关键词:
重症肌无力; 肌无力危象; 糖皮质激素; 免疫抑制剂
Keywords:
Myasthenia gravis; Myasthenia crisis; Glucocorticoid; Immunosuppressive agent
分类号:
R746.1
DOI:
10.3969/j.issn.1006-1959.2019.06.016
文献标志码:
A
摘要:
重症肌无力是发生在神经肌肉接头处、由抗体介导、细胞免疫依赖、补体参与的自身免疫性疾病，死亡率较高。肌无力危象的急救处理包括胆碱酯酶抑制剂、糖皮质激素、免疫抑制剂、静脉注射人免疫球蛋白、血浆置换、胸腺切除、机械通气等。近年来，随着国内外医疗水平的提高及免疫学研究的不断进展，对肌无力危象的治疗有了更深入的认识，其病死率呈逐渐下降趋势，使该病治愈成为可能。本文就近些年来对肌无力危象的治疗进行综述，为临床治疗提供参考。
Abstract:
Myasthenia gravis is an autoimmune disease that occurs at the neuromuscular junction, is mediated by antibodies, cellular immune dependence, and complement, and has a high mortality rate. Emergency treatment of myasthenia gravis includes cholinesterase inhibitors, glucocorticoids, immunosuppressants, intravenous human immunoglobulins, plasma exchange, thymectomy, mechanical ventilation, and the like. In recent years, with the improvement of medical standards at home and abroad and the continuous advancement of immunology research, the treatment of myasthenia gravis has gained a deeper understanding, and the mortality rate has gradually declined, making it possible to cure the disease. This article reviews the treatment of myasthenia gravis in recent years and provides a reference for clinical treatment.

参考文献/References:

[1]中国免疫学会神经免疫学分会，中华医学会神经病学分会神经免疫学组.重症肌无力诊断和治疗中国专家共识[J].中国神经免疫学和神经病学杂志,2012(6):401-408. [2]中华医学会神经病学分会神经免疫学组,中国免疫学会神经免疫学分会.中国重症肌无力诊断和治疗指南2015[J].中华神经科杂志,2015,48(11):934-940. [3]Stetefeld HR,Schroeter M.Myasthenic Crisis[J].Fortschr Neuro Psychiat,2018,86(5):301-307. [4]李尊波,熊葶,刘建军,等.短程大剂量糖皮质激素冲击联合其他免疫抑制剂治疗重症肌无力的疗效观察[J].中国神经免疫学和神经病学杂志,2015,22(7):16-19. [5]陶晓勇,黄旭升.他克莫司在重症肌无力治疗中的应用[J].中国神经免疫学和神经病学杂志,2017,24 (1):57-60. [6]Sanders DB,Guptill JT.Myasthenia gravis and Lambert-Eaton mysthenic syndrome[J].Continuum(Minneap Minn),2014,20(5):1413-1425. [7]Afanasiev V,Demeret S,Bolgert F,et al.Resistant myasthenia gravis and rituximab:A monocentric retrospective study of 28 patients[J].Neuromuscul Disord,2017,27(3):251-258. [8]Yu S,Li F,Chen B,et al.Eight-year follow-up of patients with myasthenia gravis after thymectomy[J].Acta Neurol Scand,2015,131(2):94-101. [9]Kanth KM,Solorzano GE,Goldman MD.PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents[J].Neurol Clin Pract,2016,6(2):e17-e19. [10]MacMillan D,FK506 binding proteins:cellular regulators of intracellular Ca2+ signalling[J].Eur J Pharmacol,2013,700(1-3):181-193. [11]Cataneo AJM,Felisberto G,Cataneo DC.Thymectomy in nonthymomatous myasthenia gravis-systematic review and meta-analysis[J].Orphanet J Rare Dis,2018,13(1):99. [12]冯慧宇,刘卫彬,邱力,等.血浆置换治疗重症肌无力危象的相关因素分析[J].中华医学杂志,2010,90(47):3343-3346. [13]Sieb JP.Myasthenia gravis:an update for the clinician[J].Clin Exp Immunol,2014,175(3):408-418. [14]Wu Y,Chen Y,Liu H,et al.Risk factors for developing postthymectomy myasthenic crisis in thymoma patients[J].J Cancer Res T her,2015,11(1):115-117. [15]范文君,林宏,常婷,等.胸腺切除术治疗重症肌无力的疗效及其影响因素分析[J].中国神经免疫学和神经病学杂志,2016, 23(1):1-4. [16]Uzawa A,Kawaguchi N,Kanai T,et al.Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia g ravis[J].J Neurol,2015,262(4):1019-1023. [17]Nazarbaghi S,Amiri-Nikpour MR,Mahmodlou R,et al.Clinical outcomes of myasthenia gravis with thymoma and thymic hyperplasia undergoing extended transsternal thymectomy:A single-center experience[J].N Am J Med Sci,2015,7(11):503-508. [18]Evoli A，Alboini PE，Damato V，et al. Myasthenia gravis with antibodies to MuSK: an update[J]. Ann N Y Acad Sci,2018,1412(1):82-89. [19]Tsonis AI,Zisimopoulou P,Lazaridis K,et al.MuSK autoantibodies in myasthenia gravis detected by cell based assay--A multinational study[J].J Neuroimmunol,2015(284):10-17. [20]Wolfe GI,Kaminski HJ,Aban IB,et al.Randomized trial of thymectomy in myasthenia g ravis[J].N Engl J Med,2016,375(6):511-522.

相似文献/References:

[1]刘建辉,杨 娅,况时祥,等.补脾强力复方治疗重症肌无力患者的疗效及其对 血清细胞因子的影响[J].医学信息,2019,32(16):73.[doi:10.3969/j.issn.1006-1959.2019.16.022]
　LIU Jian-hui,YANG Ya,KUANG Shi-xiang,et al.Effect of Invigorating Spleen and Strengthening Compound on Patients with Myasthenia Gravis and Its Effect on Serum Cytokines[J].Journal of Medical Information,2019,32(06):73.[doi:10.3969/j.issn.1006-1959.2019.16.022]
[2]屈娟娟,骆秀琴,缪殷姝,等.细节护理在重症肌无力患者中的应用效果[J].医学信息,2020,33(10):182.[doi:10.3969/j.issn.1006-1959.2020.10.057]
　QU Juan-juan,LUO Xiu-qin,MOU Yin-shu,et al.Application Effect of DetailedNursing in Patients with Myasthenia Gravis[J].Journal of Medical Information,2020,33(06):182.[doi:10.3969/j.issn.1006-1959.2020.10.057]
[3]高建娣,裘 妃,王秀玲.以球麻痹为唯一表现的儿童重症肌无力1例报道[J].医学信息,2020,33(23):186.[doi:10.3969/j.issn.1006-1959.2020.23.057]

更新日期/Last Update: 2019-03-15